March 29, 2024 -- PassPort Technologies, Inc. today announced positive interim clinical trial results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort®, which utilized its innovative transdermal microporation system to treat acute migraine. Zolmitriptan PassPort® was well-tolerated, with zolmitriptan detected in the plasma just 2 minutes after administration, significantly faster than the 15 minutes typically observed for oral administration. The relative bioavailability of Zolmitriptan PassPort® was approximately 160 to 200% compared to the same tablets.
Feb 23, 2024 — PassPort Technologies, Inc. (PPTI) has initiated a US Phase 1 clinical trial to evaluate the clinical trial results of Zolmitriptan PassPort®, leveraging its innovative transdermal microporation system. This PassPort® platform technology aims to provide a faster onset of action compared to the traditional zolmitriptan oral tablet, while also assessing the safety profile and pharmacokinetics of the PassPort® System.
Dec 18, 2023 — In this collaborative research, PPTI and ARCT combine their groundbreaking technologies, the transdermal microporation system PassPort® and the lipid-mediated delivery technology LUNAR®, to provide new options for mRNA vaccines and therapeutics. The LUNAR® technology is the enabling technology used in Kostaive™, the first self-amplifying mRNA COVID vaccine in the world approved in Japan on November 28, 2023. Additionally, clinical trial results demonstrate the effectiveness of the Zolmitriptan PassPort system in enhancing drug delivery.
June 5, 2023 — PassPort Technologies and IP Gaia have entered into a strategic business agreement aimed at enhancing business activities and fostering relationships with third parties around PassPort's transdermal microporation system and pipeline, which includes the promising Zolmitriptan PassPort. This collaboration is expected to leverage clinical trial results to further advance their innovative technologies.
June 10, 2022 — PassPort Technologies was recognized as one of the 'Top 10 Drug Delivery Solution Providers in 2022' by the leading print and digital publication Medical Tech Outlook. Their evaluation panel highlighted PassPort Technologies as an innovative company at the forefront of providing drug delivery solutions, including their transdermal microporation system designed to enhance the delivery of Zolmitriptan. This recognition underscores their impact on the industry and the promising clinical trial results associated with their technologies.
March 1, 2022 — Collaborative research with Japan's Josai University led to the publication of clinical trial results in March 2022 in the European Journal of Pharmaceutical Sciences. The journal article titled "Enhancement of skin permeation of fluorescein isothiocyanate-dextran 4 kDa (FD4) and insulin by thermalporation" showcased the use of a transdermal microporation system, specifically the Zolmitriptan PassPort Technologies delivery platform, to enhance skin permeation of FD-4 and improve transdermal absorption of insulin.
October 15, 2020 — Professors Ouchi (Hamamatsu University) and Suzuki (Hokkaido University) were honored as 2020 Catalyst Awardees of the Healthy Longevity Global Competition organized by the U.S. National Academy of Medicine. Their research project, which focused on the development of a novel Alzheimer's disease treatment method, utilized the Zolmitriptan PassPort® System along with an advanced transdermal microporation system to enhance the clinical trial results of a unique brain protein-derived peptide.
May 14, 2020 -- Research led by Professor Yukitoshi Nagahara will be conducted in collaboration with the Clinical Research, Innovation and Education Center at Tohoku University Hospital (CRIETO) in Japan, focusing on the clinical trial results of the innovative transdermal microporation system for delivering Zolmitriptan via the Zolmitriptan PassPort.
April 1, 2020 -- Expectations for early clinical trial results of revolutionary anticancer drugs from Tokyo University of Science are high, especially with the introduction of a novel transdermal microporation system and the innovative Zolmitriptan PassPort technology.
November 18, 2019 -- PassPort Technologies was prominently featured in a recent article published by Nikkei Business Daily. The interview, conducted with PassPort's COO, Dr. Hirotoshi Adachi, highlighted the innovative transdermal microporation system that allows for the administration of Zolmitriptan. This new technology aims to improve clinical trial results by offering an effective alternative to traditional methods such as injections and pills, making it a significant advancement in drug delivery.
October 18, 2019 -- Expecting early clinical trial results from a groundbreaking drug discovery innovation developed by Hokkaido University, which utilizes a transdermal microporation system for the administration of Zolmitriptan through the PassPort® System.
October 1, 2019 -- PassPort Technologies and Axcelead Drug Discovery Partners: Enter a comprehensive collaborative partnership in the field of drug discovery service using the PassPort® System, a new transdermal microporation system. This innovative technology aims to maximize R&D pipeline value by providing a new modality for delivering Zolmitriptan, enhancing clinical trial results.
July 1, 2019 -- Nitto Denko Corporation and the Drug Discovery Gateway Investment Limited Partnership, operated by Whiz Partners Inc., formed an alliance to accelerate the commercialization of the Zolmitriptan PassPort, an innovative transdermal microporation system designed to enhance clinical trial results.